A Multi-centric, Double blind, Placebo controlled, Randomized, observational study to evaluate the Efficacy and Safety of Carica Papaya Leaf Extract, (ZYBORICA TABLET ) as empirical therapy for thrombocytopenia associated with dengue fever

Mi Lab LifeSciencesP Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male and female patients above 18 years and below 60 years old,
•2.Patients who are confirmed to have DF or DHF grade I and II by NS1 antigen test,
•3.Patients having thrombocytopenia with at platelet count between 30,000 /micro litre to 150,000/micro litre,
•4.Patients with a baseline alanine transaminase (ALT) level of not more than 3 times of the upper limit of the normal range (not more than 165â??U/L),
•5.Patient who is willing to give informed consent to participate in study

•1.Patients with Dengue hemorrhagic fever grade III and IV,
•2.Patients with platelet count less than 30,000/micro litre,
•3.Pregnant or lactating women,
•4.Patients who have received blood or blood products transfusion during the current illness,
•5.Patients with thrombocytopenia Purpura (ITP), Leukemia, Hemophilia,
•6.Patients who have a serum ALT level 3 times higher than the upper limit of the normal range ( >165â??U/L),
•7.Impaired renal function with serum creatinine >1.5 mg/dl(males) and >1.4 mg/dl(females)
•8.Participation in another trial with an investigational drug within 1 month prior to this trial.
•9. Hypersensitivity to any of the components of the formulation,
•10.The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in this clinical study.

发起方

Mi Lab LifeSciencesP Limited